

BARBARA ANN
KARMANOS
CANCER INSTITUTE


September 13, 2007

U.S. Nuclear Regulatory Commission, Region III
Materials Licensing Branch
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

Attn: Loren Hueter
Re: Change in RSO for License #21-04127-06

This is a follow up letter to our earlier letter dated and faxed September 06, 2007. The Gershenson Radiation Oncology Center, Karmanos Cancer Institute, Detroit, MI plans to appoint Dr. Joseph Rakowski, DABR as Radiation Safety Officer (RSO) for License #21-04127-06. He will replace Mr. Vijeshwar Sharma effective immediately. Dr. Rakowski is board certified in Therapeutic Radiological Physics and Diagnostic Radiological Physics by the American Board of Radiology, has approximately 10 years of previous experience as an RSO, and meets the qualifications for this role per 10CFR35. He is currently an AMP on this license. He previously served as medical license RSO at Wilford Hall USAF Medical Center in San Antonio, TX, and at Flower Hospital in Sylvania, OH. Documentation of these appointments and his certifications are attached. If you require further assistance please feel free to contact Dr. Rakowski at (313)745-1435.

Sincerely,



Debra Herring
Vice President, Ambulatory Operations
Karmanos Cancer Institute

RECEIVED SEP 18 2007

OHIO DEPARTMENT OF HEALTH
 LICENSE FOR RADIOACTIVE MATERIAL

Pursuant to Chapter 3748 of the Ohio Revised Code, and in reliance on statements and representations made by the licensee, a license is hereby issued authorizing the licensee named herein to receive, acquire, possess, and transfer radioactive material as designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the applications of Chapter 3748 of the Ohio Revised Code and all applicable rules promulgated thereunder. This license is subject to all applicable rules, regulations and orders of the Ohio Department of Health now or hereinafter in effect and to any conditions specified below.

<p>LICENSEE</p> <p>1. Flower Hospital</p> <p>2. 5200 Harroun Road Sylvania, Ohio 43560-2196</p>	<p>LICENSE NUMBER</p> <p>3. 02120490004</p> <hr/> <p>EXPIRATION DATE</p> <p>4. July 31, 2003</p> <hr/> <p>BUREAU DOCKET NUMBER</p> <p>5. DC/CJC54-12-97</p>
---	---

6. RADIOACTIVE MATERIAL	7. CHEMICAL AND/OR PHYSICAL FORM	8. MAXIMUM QUANTITY THAT LICENSEE MAY POSSESS AT ANY ONE TIME UNDER THIS LICENSE
A. Any radioactive material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed. Not to exceed 3.7 GBq (100 mCi) Cobalt-57
B. Any radioactive material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any radioactive material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any radioactive material identified in 10 CFR 35.400	D. Any brachytherapy sources identified in 10 CFR 35.400	D. As needed
E. Any radioactive material identified in rule 3701:1-46-11	E. Prepackaged Kits	E. As needed
F. Yttrium-90	F. Any form	F. 4.1 GBq (110 mCi)
G. Uranium depleted in Uranium-235	G. Cadmium plated metal	G. As needed
H. Iridium-192	H. Brachytherapy Source Wire (Amersham Model ICW.100)	H. Not to exceed 7.4 GBq (200 millicuries) per source wire. Total possession not to exceed 11.1 GBq (300 millicuries)

6. Authorized Use

- A. Uptake, Dilution and Excretion studies per 10 CFR 35.100, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- B. Diagnostic Imaging and Localization studies per 10 CFR 35.200, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- C. Medical use described in 10 CFR 35.300, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- D. Brachytherapy procedures per 10 CFR 35.400, as delineated in rule 3701-39-02.1 of the Ohio Administrative Code.
- E. In vitro studies
- F. Calibration and reference source for Yttrium-90 Zevalin use.

OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIALS SUPPLEMENTARY SHEET	Page 2 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

- G. Shielding in a linear accelerator.
 H. For interstitial treatment of cancer.

CONDITIONS

7. Licensed material may only be used at the licensee's facilities, located at:
 Flower Hospital, 5200 Harroun Road, Sylvania, Ohio 45360-2196
 Lake Park Continuing Care Facility, 5100 Harroun Road, Sylvania, Ohio 45360-2196 (diagnostic/therapeutic administration of radiopharmaceuticals only)
8. Radiation Safety Officer for this license is:
 Joseph T. Rakowski, M.S.
9. Licensed material shall be used by, or under the supervision of, individuals designated in writing:

Authorized Users	Material and Use
A. Michael R. Hay, M.D.	A. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses.
B. Wayne S. Court, M.D.	B. 10 CFR 35.300 and 10 CFR 35.400 uses.
C. Murray A. Howe, M.D.	C. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
C. Allan S. Kaufman, M.D.	D. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
D. Blaine A. Kelgley, M.D.	E. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
E. Tamar S. Martin, M.D.	E. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses.
F. William G. Novak, M.D.	F. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
G. Parag U. Parikh, M.D.	G. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
H. David A. Parker, M.D.	H. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses.
I. Charles I. Price, M.D.	I. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
J. Thomas N. Sardelis, M.D.	J. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
K. Robin B. Shermis, M.D.	K. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
L. Phillip J. Silverman, M.D.	L. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses.
M. Daniel Singer, M.D.	M. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses.
N. Keith D. Wilson, M.D.	N. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
O. Jonathan J. Yobbagy, M.D.	O. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses.
P. Rajender K. Ahuja, M.D.	P. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire.
Q. Andre A. Konski, M.D.	Q. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire.

OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIALS SUPPLEMENTARY SHEET	Page 3 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

- | | |
|-------------------------------|---|
| R. Chun Il Mah, M.D. | R. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| S. Gerald W. Marsa, M.D. | S. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| T. William K. Mueller, M.D. | T. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| U. Steven R. Zeldner, M.D. | U. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| V. Robert S. Disalle, M.D. | V. 10 CFR 35.100, 35.200 and 3701:1-46-11 uses. |
| W. Malcom T. Doyle, M.D. | W. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses |
| X. Timothy J. Quinn, M.D. | X. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 and 3701:1-46-11 uses |
| Y. Edmund P. Ho, M.D. | Y. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| Z. Steven J. Rubin, M.D. | Z. 10 CFR 35.300, 10 CFR 35.400 and Iridium-192 wire |
| AA. Amy Culler, M.D. | AA. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 uses |
| BB. Steven Kumar Jindal, M.D. | BB. 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 uses |
| CC. Susan M. Hong | CC. 10 CFR 35.300 (excluding Iodine-131 for treatment of hyperthyroidism and thyroid carcinoma), 10 CFR 35.400 and Iridium-192 wire |
| DD. John Feldmeier, M.D. | DD. 10 CFR 35.300 & 35.400 uses. |
| EE. Vincent J. Kelsner, M.D. | EE. 10 CFR 35.100, 10 CFR 35.200 and 3701:1-46-11 uses |
| FF. Ibrahim Naveed Syed, M.D. | FF. 10 CFR 35.11, 10 CFR 35.200, 10 CFR 35.300 (limited to treatment of hyperthyroidism), and 3701:1-46-11 uses |
| GG. Dolly Razdan, M.D. | GG. 10 CFR 35.300 and 10 CFR 35.400 uses |

10. All sealed sources that are used or obtained shall have been evaluated and approved under the provisions of OAC 3701:1-46-49 or by equivalent NRC, Agreement State, or NARM licensing state regulation.
11. All person performing activities meeting the definition of "Nuclear Medicine Technologist" as specified in R.C. 4773.01 shall be licensed by, and in good standing with the State of Ohio.
12. The licensee shall establish and implement a bioassay program for all individuals involved with preparation and administration of Iodine-131 therapy doses in excess of 30 millicuries. The program shall be equivalent to that outlined in Appendix P of Regulatory Guide 10.8 Revision 2.
13. Notwithstanding the provisions of 10 CFR 35.400(d), as delineated in rule 3701-39-02.1 of the Ohio Administrative Code, the licensee may use Iridium-192 seeds encased in nylon ribbon as described in application dated April 20, 1992 and letter dated June 8, 1992 for intracavitary treatment of cancer.
14. The licensee shall follow the manufacturer's instructions for handling and cutting Iridium-192 brachytherapy source wires.
15. The licensee shall maintain records of information related to decommissioning at the location listed in item 2 of this license as specified in rule 3701:1-40-17(I) of the Ohio Administrative Code until this license is terminated by the Commission.
16. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of sealed source licensed materials to quantities below the minimum limit specified in rule 3701:1-40-17(C) of the Ohio Administrative Code for establishing decommissioning financial assurance.

OHIO DEPARTMENT OF HEALTH LICENSE FOR RADIOACTIVE MATERIALS SUPPLEMENTARY SHEET	Page 4 of 4
	License Number 02120490004
	Bureau Docket Number: DC/CJC51-12-97
	Amendment No. 11

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Ohio Department of Health's statutes, rules, and orders shall govern unless statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 15, 1998.
 - B. Letters dated August 19, 1998; March 24, 1999; September 20, 1999; February 8, 2000; March 30, 2000; November 21, 2000; August 17, 2001 & December 4, 2001.
 - C. Correspondence on USNRC license number 34-15184-01, Amendment number 40.
 - D. Telefacsimile dated February 15, 2000.
 - E. Letter dated March 25, 2002.
 - F. Letter dated June 11, 2002.
 - G. Letter dated December 30, 2002, facsimiles dated January 29, 2003 and February 18, 2003.
 - H. Letter dated February 20, 2003 requesting change in RSO to Joseph Rakowski, M.S.

For the Ohio Department of Health

DATE: 3/10/03

BY: Roger L. Szymanski
 Director, Ohio Department of Health



DEPARTMENT OF THE AIR FORCE
HEADQUARTERS UNITED STATES AIR FORCE
BOLLING AFB DC 20332-6188

REPLY TO: AFOMS/SGPR
ATTN OF: BROOKSAFB, TEXAS 78235-5000

29 JAN 1988

SUBJECT: USAF Radioactive Material Permit No. 42-02682-2AFP

TO: Wilford Hall USAF Medical Center/SGHQRP
Lackland AFB, Texas 78236-5300

Attached is Amendment No. 2 to USAF Radioactive Material Permit No. 42-02682-2AFP amending Conditions 23 and 28. Please reference all future correspondence concerning this action to Permit No. 42-02682-2AFP and Docket No. 030-00505.

Lawrence Donovan
Lawrence Donovan, Major, USAF, BSC
USAF Radioisotope Committee
Office of the Surgeon General

1 Atch
Amendment No. 2 to Permit No.
42-02682-2AFP

cc: HQ JMMC/CC
Randolph AFB, Texas 78150-5000

HQ ATC/SGPB
Randolph AFB, Texas 78150-5001

USNRC, Region IV
Arlington, Texas 76011

RADIOACTIVE MATERIAL PERMIT
USAF RADIOISOTOPE COMMITTEE
SUPPLEMENTARY SHEET

PAGE 1 OF 1 PAGES

PERMIT NO.
42-02682-2AFP

AMENDMENT NO.
2

DOCKET NO.
030-00505

Wilford Hall USAF Medical Center/SGHQRP
Lackland AFB, Texas 78236-5300

USAF Radioactive Material Permit No. 42-02682-2AFP is amended to read as follows:

23. Capt Joseph T. Rakowski is designated Radiation Safety Officer. Lt Col Kenneth N. Vanek is designated Alternate Radiation Safety Officer.
28. Except as specifically provided otherwise by this Permit, the possession and use of the radioactive material described in Items 6, 7, and 8 above shall be in accordance with the statements, representations, and procedures contained in letters dated 20 Jul 1982, 12 Oct 1982, 16 Jun 1983, 17 Feb 1983, 8 Feb 1984, 2 May 1985, 31 Aug 1987, 13 Nov 1987, and 25 Jan 1988. The Nuclear Regulatory Commission's regulations and United States Air Force directives shall govern the permittee's statements in applications or letters, unless the statements are more restrictive than the regulations and directives.

Date 29 JAN 1988

FOR THE USAF RADIOISOTOPE COMMITTEE

By Lawrence Donovan

The American Board of Radiology

Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine
Hereby certifies that


Joseph Tobias Rakowski, PhD

Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of
The American Board of Radiology

On this seventh day of June, 2005

Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of

Therapeutic Radiologic Physics



Certificate No. H1749

Steven A. Litch, M.D.
President

Richard T. Hoppe MD
Secretary-Treasurer

R.P. Hatten MD
Executive Director



Valid through 2015

The American Board of Radiology

*Organized through the cooperation of the
American College of Radiology, the American Roentgen Ray Society,
the American Radium Society, the Radiological Society of North America,
the Section on Radiology of the American Medical Association,
the American Society for Therapeutic Radiology and Oncology, the Association of
University Radiologists, and American Association of Physicists in Medicine*

Hereby certifies that

Joseph Tobias Rakowski, MS


*Has pursued an accepted course of graduate study
and clinical work, has met certain standards and qualifications and
has passed the examinations conducted under the authority of*

The American Board of Radiology

On this fourth day of November, 1996

*Thereby demonstrating to the satisfaction of the Board
that he is qualified to practice the specialty of*

Diagnostic Radiologic Physics



Laurel S. Tomasson, MD
President

Robert R. Hartung, MD
Secretary-Treasurer

M. Paul Capp, M.D.
Executive Director



BARBARA ANN
KARMANOS
CANCER INSTITUTE
*Detroit Medical Center
Wayne State University*

*In Partnership With
The Detroit Medical Center
Wayne State University
Michigan Cancer Foundation*

*Gershenson Radiation Oncology Center
~~48201~~
Detroit, MI ~~48201~~*

CERTIFIED MAIL™



7003 0500 0004 7557 5011

UNITED STATES POSTAGE

THIRTY BONES
02 1A
0004370916
MAILED FROM ZIP CODE 48201
\$ 05.380
SEP 14 2007

U.S. Nuclear Regulatory Comm., Region III
Materials Licensing Branch
2443 Warrenville Rd., Suite 210
Lisle, IL 60532-4352

605324352 0021

